Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DICLOFENAC vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diclofenac inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Ankylosing spondylitis,Osteoarthritis,Rheumatoid arthritis,Acute migraine (oral formulation),Mild to moderate acute pain (off-label),Dysmenorrhea (off-label)
Mild to moderate pain,Fever
Oral: 50 mg twice daily or 75 mg twice daily; maximum 150 mg/day. Topical: apply 4 times daily. IM: 75 mg once daily.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life ~2 h (diclofenac immediate-release); enterohepatic recirculation may produce secondary peaks. Clinical context: Short half-life requires multiple daily dosing for sustained effect.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily hepatic via CYP2C9 (major) and CYP3A4 (minor); undergoes glucuronidation. Metabolites include 4'-hydroxydiclofenac, 5-hydroxydiclofenac, and 3'-hydroxydiclofenac.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal (65% as metabolites, <1% unchanged); biliary/fecal (35% as metabolites).
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
>99% bound primarily to serum albumin.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
0.1-0.2 L/kg (low distribution, reflects high protein binding). Clinical meaning: Limited extravascular distribution; primarily remains in vascular space.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral immediate-release: ~50% due to extensive first-pass metabolism; Topical: <10% systemic; Ophthalmic: minimal; IV: 100%.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
GFR >30 m L/min: no adjustment. GFR 15-30 m L/min: use with caution, reduce dose, avoid if possible. GFR <15 m L/min: contraindicated.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Children ≥1 year: oral 0.5-1 mg/kg/dose twice daily; maximum 3 mg/kg/day or 150 mg/day. Children ≥14 years: same as adult.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Start at lowest effective dose, e.g., 25-50 mg/day oral; increase cautiously. Avoid NSAIDs in advanced age due to GI and renal risks.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Diclofenac is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Cardiovascular risk: increased risk of thrombotic events, hypertension, and heart failure.,Gastrointestinal risk: increased risk of serious GI adverse events including bleeding, ulceration, and perforation.,Renal toxicity: monitor renal function in patients with preexisting renal disease, dehydration, or concomitant nephrotoxic agents.,Hepatic toxicity: elevated liver enzymes; rare cases of severe hepatic reactions.,Anaphylactoid reactions: can occur in patients with or without known NSAID hypersensitivity.,Fluid retention and edema: use with caution in patients with hypertension or heart failure.,Skin reactions: serious cutaneous adverse reactions such as Stevens-Johnson syndrome and DRESS.,Hematologic: prolonged bleeding time; use with caution in patients with coagulation disorders.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Known hypersensitivity to diclofenac or any component of the formulation,History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs,Perioperative pain in the setting of CABG surgery,Active GI bleeding,Severe uncontrolled heart failure,Advanced renal disease (unless dialysis is ongoing),Third trimester of pregnancy
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid alcohol as it increases risk of GI bleeding. Take with food or milk to minimize GI irritation. No specific food restrictions, but high-fat meals may delay absorption.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
First trimester: Increased risk of spontaneous abortion and congenital malformations (cardiac defects, gastroschisis) due to prostaglandin synthesis inhibition. Second trimester: Risk of oligohydramnios and fetal renal impairment with prolonged use. Third trimester: Avoid after 30 weeks gestation; risk of premature closure of ductus arteriosus, persistent pulmonary hypertension of the newborn, and oligohydramnios.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Excreted in breast milk in low amounts; M/P ratio not reported. Use with caution; avoid in breastfeeding mothers with infants with thrombocytopenia or platelet dysfunction. Consider risk of infant renal impairment.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No dose adjustment recommended for pharmacokinetic changes; however, use at lowest effective dose for shortest duration. Avoid in third trimester due to fetal risks. Consider alternative analgesics in all trimesters.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Diclofenac is a potent NSAID with a short half-life, making it suitable for acute pain but requiring frequent dosing. It carries a higher risk of cardiovascular events compared to other NSAIDs; caution in patients with hypertension or heart disease. Enteric-coated formulations may delay onset but reduce GI irritation. Intravenous formulation allows for rapid analgesia but requires monitoring for hypertension and fluid retention. Diclofenac can cause elevation of liver enzymes; monitor LFTs with long-term use. It is available in combination with misoprostol to reduce GI ulcer risk.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication to lower risk of stomach bleeding.,Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or aspirin without consulting doctor.,Report signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds) or chest pain immediately.,May cause dizziness or drowsiness; avoid driving until you know how this drug affects you.,Limit sun exposure and use sunscreen as this drug may increase sun sensitivity.,Do not use in third trimester of pregnancy as it may harm the unborn baby.,Store at room temperature away from moisture and heat.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
"Ximelagatran, an oral direct thrombin inhibitor, increases the risk of bleeding when coadministered with diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). The combination potentiates anticoagulant activity through additive inhibition of platelet aggregation and thrombin-mediated coagulation, elevating the risk of gastrointestinal hemorrhage and other serious bleeding events. Patients, particularly those with renal impairment or advanced age, require close monitoring for signs of bleeding."
"Acebutolol, a cardioselective beta-blocker, may attenuate the antihypertensive effect of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). Diclofenac inhibits cyclooxygenase, reducing prostaglandin synthesis, which can lead to sodium retention and increased vascular resistance, thereby counteracting the blood pressure-lowering effects of acebutolol. This interaction may result in diminished blood pressure control, potentially requiring dose adjustments of antihypertensive therapy."
"Enzalutamide, a potent CYP3A4 inducer, significantly reduces the exposure of diclofenac, a CYP2C9 substrate, by increasing its hepatic metabolism. This interaction can lead to subtherapeutic diclofenac concentrations, thereby diminishing its analgesic and anti-inflammatory efficacy. Clinically, patients may experience inadequate pain control or exacerbation of inflammatory conditions, such as arthritis, when these agents are coadministered."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DICLOFENAC vs ACEPHEN, answered by our medical review team.
DICLOFENAC is a NSAID that works by Diclofenac inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DICLOFENAC and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DICLOFENAC is: Oral: 50 mg twice daily or 75 mg twice daily; maximum 150 mg/day. Topical: apply 4 times daily. IM: 75 mg once daily.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DICLOFENAC and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DICLOFENAC is classified as Category D/X. First trimester: Increased risk of spontaneous abortion and congenital malformations (cardiac defects, gastroschisis) due to prostaglandin synthesis inhibition. Second trimester: R. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.